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Abstract High performance liquid chromatography coupled
with triple-quadrupole mass spectrometry was applied in the
determination of in vitro metabolism products of selected
antibiotic drugs (cefotaxime, ciprofloxacin, fluconazole,
gentamicin, clindamycin, linezolid, and metronidazole). The
analytes were separated on a reversed phase C18 column, with
acetonitrile and 0.1 % aqueous formic acid as the mobile
phase. Tandem mass spectrometry with positive electrospray
ionization was used to facilitate the structural characterization
of the potential metabolites. Metabolism studies on human
liver microsomes were performed via cytochromes P450
(phase I) and via NADPH/UDP-glucuronosyltransferase
(phase II) mediated reactions. LC-MS/MS experiments
allowed potential metabolite peaks, including sum formulae
suggestions, to be identified; high resolution MS/MS experi-
ments led to the identification of various oxidative and reduc-
tive modifications of target compounds in phase I biotransfor-
mation, and conjugation products with glucuronic acid in
phase II reactions. A total of 11 potential metabolites and their
proposed structures were characterized during the incubation
of human liver microsomes by comparing their retention times
and spectral patterns with those of the parent drug.
Dehydrogenation and reactions of side chains such as
hydroxylation and hydrolysis of ester bonds constituted the
major metabolic pathways. Finally, LC-MS/MS spectrometry
was revealed to be a suitable analytical tool to procure a feasible
analytical base for the envisioned in vivo experiments.
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Introduction
In recent years, a significant interest regarding bacterial infec-
tions could be observed. Moreover, resistance to commercial-
ly available antimicrobial agents by pathogenic microorgan-
isms has been increasing at an alarming rate and has become a
serious global problem for healthcare. On the other hand, ther-
apeutic drug monitoring (TDM) referring to the individualiza-
tion of dosage is an important aspect of interdisciplinary ap-
proach towards such studies. Therefore, TDM will be more
valuable, which will make it possible to personalize and opti-
mize therapeutic practices and healthcare system. Moreover,
in view of the diverse and unique pharmacokinetic profile of
drugs in patients undergoing treatment for bacterial infections,
there is a need to use TDM in an attempt to optimize the
exposure to antibiotics, improve clinical outcome, and limit
the alarming occurrences of antibiotic resistance in bacteria
[1–3]. Antibiotics are a class of antimicrobials, a larger group
that also includes anti-viral, anti-fungal, and anti-parasitic
drugs. They are among the most frequently prescribed medi-
cations in modern medicine. There is a wide range of antibi-
otics, and the choice of what to administer to a patient depends
on which kind of infection it is and which types of antibiotics
are known to be effective against it as different classes of
antibiotics combat bacterial infections in different ways.
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They are widely prescribed; however, the fact that microor-
ganisms are developing resistance to these drugs means that
their efficacy may be lost and care should be taken to avoid
unnecessary administration [4, 5].
crosomal approaches using human liver microsomes (HLMs).
Liver is the major organ involved in the biotransformation of
various endogenous compounds and drugs. Moreover, liver
cells show a high level of cytochrome P450 activity and often
are the main site of metabolic transformation. Liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
has become a powerful and reliable analytical approach for
metabolite quantitation because of its high sensitivity, low
consumption, and high speed of analysis [6–16].
increased throughput screening assays have been developed to
determine the metabolic stability of drugs. Two experimental
systems—liver microsomes and intact hepatocytes—are cur-
rently widely applied (Fig. 1). Moreover, combining electro-
chemistry with mass spectrometry creates a powerful analyti-
cal tool for metabolite studies and helps overcomemany of the
laborious tasks by isolating the metabolites formed in vivo
(blood, plasma, urine) or in vitro (microsomes, artificial vein
system (HLM) [15].
researched analytes (cefotaxime, ciprofloxacin, fluconazole,
gentamicin, clindamycin, linezolid, and metronidazole) with
human liver enzymes of microsomal fraction (HLM), a study
was undertaken to elucidate this issue. To the best of our
knowledge, no detailed information regarding the structure
of their potential metabolites via in vitro studies has been
published. In this study, we applied LC/MS to identify phase
I and phase II metabolites of the studied biologically active
compounds detected after in vitro incubation of the
researched. Transformations were investigated with HLM
and in the presence of NADPH/UDPGA-P450 oxidoreduc-
tase. Additionally, obtained results were compared to in vivo
studies with the use of biological samples from patients. The
results obtained will allow predicting metabolic pathways of
target compounds in patients differing in the level of cyto-
chrome P450 isoenzymes and, in turn, can probably be helpful




Cefotaxime (CEF), ciprofloxacin (CIP), fluconazole (FLU),
gentamicin (GEN), clindamycin (KLI), linezolid (LIN), met-
ronidazole (MET), and gemifloxacin (GEMI) (internal stan-
dard, IS) were obtained from Sigma-Aldrich (Schnelldorf,
Mittelfranken, Germany). Glucose-6-phosphate, β-NADP+,
Fig. 1 Scheme of isolation of
subcellular microsomal fractions
applied in evaluation the in vitro
metabolism of biologically active
compounds
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Typical in-vitro methods in metabolic studies include mi-
Because the liver is the major organ for drug metabolism,
As there are no publications regarding the interaction of the
glucose-6-phosphate dehydrogenase, and uridine 5′-
diphosphoglucuronic acid triammonium salt (UDPGA) were
obtained from Sigma-Aldrich (Schnelldorf, Mittelfranken,
Germany). Other chemicals of analytical quality (acetonitrile,
formic acid) were purchased from Merck (Darmstadt,
Germany). Microsomes derived from human liver cells
(HLMs) at the concentration of 10 mg/vial were used in en-
zymatic studies. The microsomal fractions were stored at –80
°C and thawed immediately before each experiment.
Ultrapure water was used for all analyses. Other chemicals
were all analytical reagents. The water was obtained bymeans
of Milli-Q RG apparatus by Millipore (Millipore Intertech,
Bedford, MA, USA) in our laboratory. Drug-free urine was
kindly provided by Nicolaus Copernicus University,
Collegium Medicum, Torun (Poland) with Bioethical
Commission permission (no. 639/2010).
Phase I in vitro incubation
The antibiotic drug incubation (concentration 1–25 μm) with
HLMs was performed in phosphate buffer (pH 7.4) at 37 °C.
Then, the incubated samples were shaken for a specified time
at 120 rpm. The optimization of conditions for carrying out the
process included the incubation time, the concentration of
HLM, the concentration of analytes, and the reaction buffer
consisting of an enzymatic reaction cofactor NADP/NADPH,
glucose-6-phosphate dehydrogenase, and magnesium ions.
The blank samples were of the same composition as the test
samples; however, they did not contain any of the studied
biologically active compounds. The process was terminated
with 50 μL of ice-cold ACN. Thereafter, samples were imme-
diately prepared and analyzed with the use of HPLC-UV/MS.
All samples were prepared in triplicate. Glucuronidation was
studied by incubation of the model drug with HLMs. The test
and blank samples were prepared analogously to phase I me-
tabolism samples, the exception being that 10 μL of PB
contained the UDPGA co-factor, which mediated the relevant
reaction. All samples were incubated and treated as described
above and as also described in detail in reference [16].
Cancer cell line
Human Caucasian colon adenocarcinoma cell line (Caco-2)
was obtained from ECACC (European Collection of Cell
Cultures, UK). Cells were cultured in Dulbecco’s modified
Eagle medium – high glucose 4.5 g/L Sigma-Aldrich
(Schnelldorf, Mittelfranken, Germany), supplemented with
20 % (v/v) inactivated fetal bovine serum (PAA Laboratories
GmbH, Pasching, Austria) and 1 % (v/v) nonessential amino
acids (Biological Industries, Kibbutz Beit-Haemek, Israel).
Additionally, gentamycin from Sigma-Aldrich (Schnelldorf,
Germany) was added to the culture media at the concentration
0.04 mg/mL. The study used a special culture dish in the form
of a closed, two-chamber container. Between the upper and
the lower chamber, there was a horizontal porous membrane
on which a culture of epithelial cells grew. Both the upper
(apical) and the lower (basal) chamber were filled with growth
medium. The pH of the growth medium on the apical side was
6.5, whereas on the basal side it was 7.4, which simulates
in vivo conditions. Cells were cultured at 37 °C in humidified
atmosphere of 5 % CO2. Caco-2 cells were plated in 96-well
plates (Thermo Fisher Scientific, Nunc, Denmark) at the
density of 6 × 104 cells per cm2 and grown for 72 h. Then
the medium was aspirated for 12 or 24 h. Finally, gentamicin
and its potential metabolites were analyzed after filtration
from the culture medium.
Chromatography and mass spectrometry
The presented procedure is based on the procedure described
in reference [16]. An overview of the tandem mass spectrom-
etry (MS/MS) settings is listed in Table 1.
Calibration and validation
Avalidation of the developed method was performed accord-
ing to the appropriate approaches described in detail in refer-
ences [16–18].
Sample preparation – urine assay
Results
In vitro incubation of selected antibiotic drugs
with human liver microsomes
Human liver microsomes were applied during performed in-
vestigation. Seven antibiotic drugs different in physicochem-
ical structure were included in the incubation tests, namely
ciprofloxacin (CIP), cefotaxime (CEF), fluconazole (FLU),
gentamicin (GEN), clindamycin (KLI), linezolid (LIN), and
metronidazole (MET). To select the right conditions for the
experiment, initially the studied compounds were incubated in
the conditions appropriate for carrying out the process, which
included several parameters such as the incubation time (0–
120 min), concentration of HLM (0.2–1.6 mg/mL),
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The patient urine samples contained slight amounts of urine
proteins; therefore, a protein pretreatment was necessary. Three
mL of acetonitrile was added to 1.5 mL of the urine sample to
remove the protein. Themixture was shaken for 10min and then
centrifuged at 7500×g force to obtain 4 mL of the supernatant.
The supernatant was diluted with a mobile phase and then was
filtered through a 0.22-mm microporous membrane. The
filtrated samples were used for HPLC measurements.
concentration of the selected antibiotic drug (10–25 μM), and
reaction buffer consisting of an enzyme reaction cofactor
NADPH/UDPGA (1.5–30 mM), glucose-6-phosphate (G-6-
P) (0.5–15 mg/mL), dehydrogenase (0.8–24 U/mL), and mag-
nesium ions (1.5–7.5 mM). The incubation with enzymes of
microsomal fraction was performed in phosphate buffer
(pH 7.4) at 37 °C. Heating of liver microsomal fraction en-
zymes at 37 °C for a set period of time in the absence of
NADPH had no influence on the amount of the substance in
the reaction mixture. In other words, the collected results sug-
gest that the studied antibacterial medicines were susceptible
to enzymatic transformations in the presence of metabolic
biotransformation cofactor, and the degree to which they
reacted depended both on the concentration of NADPH and
on the incubation length. The results are illustrated in Fig. 2,
with fluconazole serving as reference. As the graph displays,
the concentration of the substrate showed linear decrease as
the reaction progressed.
Identification of antibiotic drugs metabolites
The analysis of the presented MS chromatograms reveals that
most of the studied antibiotic drugs undergo enzymatic trans-
formations very easily, and the yield depends on the presence
and concentration of NADPH and on incubation time.
Biotransformation of the target compounds leads to creation
of one, two, or three main products (Fig. 3). Based on the
gathered results, a conclusion was drawn that there were me-
tabolites of the phase I of biotransformation reaction, and me-
tabolites of phase II. The potential metabolites were assigned
the numbers M1–M3 referring to their retention times.
mentation for a selected protonated molecule (a potential me-
tabolite) confirmed the validity of their postulated chemical
structures. This is in agreement with the general knowledge
that this group of cytochrome P450 isoenzymes participates in
metabolism of numerous drugs. However, for certain products
the peaks were of low intensity, whereas a large fraction of the
substrate had reacted and concentration of the products de-
creased with time of the reaction; finding an explanation of
this phenomenon turned out to be a problem. One may spec-
ulate that the appearing reactive metabolites quickly bind to
the surface of microsomal proteins present in the mixture at
high concentration. In case of CIP, M1 metabolite was ob-
served at m/z 288, which points to decarboxylation of the side
chain. Additionally, in the presence of the other enzymatic
reaction cofactor, UDPGA, the creation of potential M2 me-
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On the basis of the results obtained, the following param-
eters were applied for further studies: 120 min of incubation
time; 0.4 mg/mL of HLM, 10 μM of selected antibiotic drug,
5 mM of NADPH/UDPGA, 10 mg/mL G-6-P, 16 U/mL of
dehydrogenase, and 5 mM of MgCl2.
Additionally, the experiments on two-stage MS/MS frag-
to conjugation of the basic drug with glucuronic acid. As a
result, the MS/MS spectrum revealed a loss of a defined neu-
tral fragment – glucuronic acid (Δ-176 Da) and a signal from
the secondary ion form/z 208, which appears during fragmen-
tation of a precursor ion for the resulting compound. For FLU,
metabolite M1 was observed at m/z 323, indicating hydroxyl-
ation of the aromatic moiety. In case of GEN, metabolite M1
corresponded to m/z 520, indicating acetylation. Moreover, in
the presence of UDPGA, the creation of potential M2 metab-
olite was observed ([M +H]+ for m/z 654), corresponding to
conjugation of the basic drug with glucuronic acid. For KLI,
the obtained metabolites at m/z 411 and 441 are probably
associated with the S-dealkylation or N-dealkylation and S-
oxidation, respectively. In case of MET, metabolites M1 (m/z
142) and M2 (m/z 188) correspond to reduction of nitro
groups and oxidation of aliphatic chains, respectively.
Furthermore, in the presence of UDPGA, the creation of po-
tential M3 metabolite was observed ([M +H]+ for m/z 348),
and corresponding conjugation of the basic drug with glucu-
ronic acid. Table 2 presents the retention times, chemical
structures, m/z ratio, composition, and proposed biochemical
reaction for each of the chosen antibacterial drugs. Moreover,
the protonated molecular ions, retention times, and main MS2
product ions of target compound metabolites are presented in
Table 2.
In vitro studies with the use of Caco-2 cell line
With the knowledge of the directions that metabolic transfor-
mations of gentamycin as a model compound in the enzymatic
system can take, it was decided that the next step in the re-
search would be to study its biotransformation in another area
of its expected therapeutic (bactericidal) action (i.e., in cancer
cells of the Caco-2 line). An appropriate chromatographic
image of the contents of methanol extracts isolated from
Caco-2 cells was obtained for cell concentration of 2 × 103,
gentamycin concentration of 100 μg/mL, and incubation time
of 6, 12, and 24 h. Based on the collected results, it was
concluded that Caco-2 cells at this stage of growth show met-
abolic activity. The studies of timed exposure of Caco-2 cul-
ture to the studied substance proved that intestinal epithelial
cells can activate processes leading to biotransformation of the
drug. Studies on metabolic biotransformation of gentamycin
in the presence of enzymes of Caco-2 cell line reveal that at
least three mainmetabolites are created. TheMS spectra of the
peaks of M1, M2, and M3 products contain mainly mass ions
with respective values of 520, 576, and 654. The growth of the
molecular weight of the substrate (gentamycin), by 42, 96, and
176 units, respectively, signifies that these entities are prod-
ucts of phase II metabolic reactions. It was also observed that
the reactions occur independently of each other.
Chromatographic analysis revealed the presence of three
GEN metabolites (Fig. 4). It can be concluded that the drug
penetrated epithelial cells to a slight degree and underwent
metabolic transformations. After 24 h of reacting, the charac-
teristic signals from potential metabolites were disappearing,
which could be caused by their instability. The peak of M2
metabolite is particularly interesting as although its intensity
decreases with incubation time, it is still present in the mixture
after 24 h. The appearance of a new metabolite, which had not
been observed during the transformation of the chosen analyte
in the presence of human microsomes, underlines the existing
differences concerning how easily they undergo metabolic
transformations in the presence of microsomal proteins found
in various models for in vitro studies. This knowledge can be
helpful to prognose the influence of the studied antibiotic
Fig. 2 The influence of the
presence of enzymatic reaction
cofactor-NADPH for antibiotic
drug (FLU) conversion. Pre-
incubation of human liver
microsomes at 37 °C before the
NADPH addition (black diagram)
and with pre-incubation of HLMs
together with NADPH (gray
diagram)
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drugs on the activity of metabolizing enzymes and in planning
a targeted therapy. However, such interactions can be different
in vivo. The results derived from this approach were com-




Fig. 3 Representative extracted ion chromatogram of potential metabolites produced following the incubation with human liver microsomes for (a) CIP;
(b) FLU; (c) GEN; (d) KLI, and (e) MET
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by analyzing real urine samples from patients after antibiotic
drugs have been administered. Table 2 may be consulted in
order to obtain a quick overview of all metabolites discussed
in this study, with specific reference to their chemical struc-
ture, mass data, and fragmentation patterns.
Method validation
After the sample preparation and HPLC/MS conditions were
defined, a validation was performed to assess the performance
of the proposed methods. Intra-day accuracy and precision of
target compounds in human liver microsomes are shown in
Table S2 (see Electronic Supplementary Material, ESM).
Accuracy and precision results are presented in Table S3
(see ESM). Stability of the target compounds in biological
samples was tested at three concentration levels (1, 7, and
15 μg/mL) under different conditions. The results of stability
tests for biological samples are presented in Table S4 (see
ESM). Additionally, possible matrix effect on the signals for
target compounds was evaluated by studying the difference
between the mass spectrometric signal for studied antibiotic
drugs in standard solutions and the signal for these com-
pounds in a biological matrix (e.g., HLM). Less than 15 %
matrix effect was observed for studied antibiotic drugs.
Discussion
The HPLC parameters for the HPLC-UV-MS/MS method
were selected after screening a number of columns and solvent
systemswith different isocratic profiles. The conditions select-
ed in the developed procedure (see Experimental section) gave
excellent determination with run time lower than 15 min. To
select the LC-MS/MS parameters, a standard amount of 1 μg/
mL of target compoundwas injected into the HPLC column in
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mode provided the best response, where the protonated mo-
lecular ion [M +H]+ relevant for the target antibiotic drug was
monitored very well on the MS chromatograms. Some param-
eters of ESI source such as capillary voltage (3500–4500 V),
nebulizer gas pressure (30–40 psi), drying gas flow (6–8 L/
min), drying gas temperature (290–350 °C), and fragmentor
voltage (75–255 V) were optimized to obtain most intense
detector response (see ESM Fig. S1). Each parameter was
Table 2 The retention times, mass characteristics and elemental composition of the [M +H]+ of studied antibiotic drugs and their potential metabolites
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optimized separately. Mass spectrometric detection was per-
formed using electrospray and the mass spectrometer was op-
erated in multiple reaction monitoring mode. The described
analytical method was prepared for simultaneous qualitative
analysis of target antibiotic drugs and their potential metabo-
lites. Each of the antibiotic drugs was also quantified.
structures of the products that are the outcome of metabolic
biotransformation of the tested drugs. For this purpose, mass
spectra were recorded for each studied analyte (substrate)
and potential metabolite (product) with HPLC-ESI/MS tech-
nique. There is a vast number of individual components in
human liver microsomal fraction enzymes that can elute
during the analysis at the same time as the target substance.
To solve this problem, the study utilized Mass Hunter
Metabolite ID. software. With this tool, the signals coming
from a given analyte were compared with reference samples
with regard to their retention times, MS spectra, and areas.
To fulfill requirements for confirmatory methods, two tran-
sitions were monitored for each analyte. For each analyte,
one transition was chosen for quantification, and the second
was used for confirmation. MS/MS was used to determine
whether the fragmentation of target compounds is specific
and makes it possible to identify them in the next stages of
research (e.g., during the determination and identification of
potential metabolites). The most intense signal on the full
scan spectra was chosen as the parent ion. The first stage of
research was focused on the selection of collision energy,
which was tested in the range of 20 to 40 eV, increasing
energy of 1–5 eV. The obtained results showed that MS/MS
will be useful in further studies as a tool for qualitative
analysis because of the vast possibility to confirm the struc-
ture of the metabolites produced on the basis of the product
ion spectra. Detailed MS-MS conditions are listed in
Table 3. Ion groups [M +H]+ for the proposed metabolites
were initially determined and identified in full scan mode.
With preselected mass spectrometer analysis conditions,
CEF was identified as [M +H]+ for m/z 456, CIP as [M +
H]+ for m/z 332, FLU as [M +H]+ for m/z 307, GEN as
[M +H]+ for m/z 478, KLI as [M +H]+ for m/z 425, LIN
as [M +H]+ for m/z 338, and MET as [M +H]+ for m/z 172.
Multistage fragmentation of target compounds was carried
a
b
Fig. 4 Total ion chromatograms and mass spectra of gentamicin and their potential metabolites after incubation with Caco-2 cell line: (a) after 6 h, (b)
after 12 h, (c) after 24 h, (d) UV chromatogram after 12 h and 24 h. Mass spectrometric detection was carried out in ESI(+) mode
Study of in-vitro metabolism of selected antibiotic drugs 8281
Moreover, an attempt was made to determine chemical
out in order to gather data for interpreting MS spectra of
potential metabolites of the selected drugs.
performed under a wide range of incubation conditions and
were monitored by HPLC-UV/MS. The rates of substrate
transformations were calculated as the ratio of the substrate
HPLC peak height after a given time of incubation to the
initial peak height of the substrate. On the basis of the results
obtained for cefotaxime and linezolid, one can conclude that
they are not in the substrate spectrum of the action of the
studied enzymes. Besides cytochrome P450, other important
elements of microsomal fraction of liver cells include flavin
monooxigenase (FMO) and glucuronosyltransferase (UDP).
Research on linezolid and cefotaxime, which contain a
methoxyl group instead of a hydroxyl one, aimed at establish-
ing potential substrate properties in the presence of another
metabolizing enzyme. Thus, in research on determining the
enzyme groups present in microsomal vesicles of liver cells
that can participate in transformation of the studied analytes,
the next step was to check how easily LIN and CEF undergo
transformations in the presence of phase II metabolic enzymes
– glucuronosyltransferases (i.e., UGT). Considering the above
described reactivity of these compounds observed after
incubation with a mixture of microsomal enzymes, the out-
come of the tests run for linezolid and cefotaxime was surpris-
ing. As a consequence, it led to formulating several possible
working hypotheses. One can assume that LIN and CEF, ow-
ing to their chemical structure and pharmacological properties,
do not constitute a substrate for any of the tested isoenzymes
of cytochrome P450. It is thus possible that other isoenzymes
belonging to cytochrome P450 play a part in the metabolism
of the studied drugs. Therefore it is likely that metabolic pro-
cesses occurring outside liver cells can be important for bio-
transformation of both substances. Considering this, metabo-
lism in liver cells seems not to be the only way these sub-
stances are transformed. As metabolic transformations of the
selected drugs in the presence of human liver microsomal
fraction enzymes were observed, it was concluded that these
substances showed varied ability to transform. The collected
results allowed us to determine that human microsomes are an
appropriate material for research as well as for making a prog-
nosis concerning the metabolic transformations that the tested
analytes can be undergoing in a patient’s organism. Enzymatic
transformations of the chosen substances in the presence of
microsomal enzymes were conducted in conditions selected
with the aim to activate an appropriate antibacterial drug.
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Studies on the metabolism of target compounds were car-
ried out with human liver microsomes. The reactions were
Table 3 Ions observed by ESI-MS/MS
Compound/precursor ion 
[m/z] 




Proposed chemical formula 
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cells, the ones most involved in biotransformations of foreign
substances are isoenzymes of cytochrome P450; ca. 95 % of
currently used medicines are metabolized by this group of
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microsomal fraction enzymes used in this study, together with
their enzymatic activity.
UV-Vis spectra (data not presented) of biotransformation
products of specific medicines supports the assumption that
in their particles, changes in the side chain can be expected. In
the case of ciprofloxacin, the changes in the structure of the
drug molecule occur in the carboxyl group. In the case of
fluconazole, the changes in molecule structure resulting from
enzymatic biotransformation concern the benzyl group.
During the tests, no phase II product was observed for flucon-
azole and clindamycin. Probably these drugs do not undergo
phase II biotransformation reactions in the presence of
glucuronosyl transferase enzymes located in the microsomal
fraction of human liver. To confirm the noticeable participa-
tion of UGT in creating phase II biotransformation products
for the other medicines, β-glucuronidase was added to the
reaction mixture. Activity of this enzyme results in hydrolysis
of glucuronides [20]. During incubation in the presence of
bacterial enzyme, it was noticed that the peaks of products
of metabolic glucuronidation were gradually disappearing.
This observation is also a proof that in a living organism there
is a relation between phase I and phase II of metabolism.
Besides, the presence and the appropriate level of NADPH-
dependent cytochrome P450 reductase in liver cells is a nec-
essary condition for proper physiological actions of its isoen-
zymes. Interpretation of the collected mass spectra of the
peaks of the obtained metabolites allows us to conclude that
the other studied antibacterial drugs easily undergo enzymatic
transformations in the presence of selected co-substrates. The
m/z values of their mass ions can correspond to chemical
structures of the products in which, after the first phase of
metabolic transformations, there occurred conjugation of the
given medicine with the glucuronic acid radical (Δ-176 Da)
through the oxygen atom in the drug particle. Presence of such
metabolites also confirms the supposition that a product of
phase I of metabolic biotransformation is further transformed
during phase II, in this case by glucuronidation.
ence, no signals coming from other substances were observed
during the analysis. The testing also included the susceptibil-
ity of the chosen analytes to transformations when exposed to
phase II metabolic enzymes present in the microsomal vesi-
cles of liver cells, i.e., glucuronosyltransferases (UGT). They
are responsible for metabolizing a wide range of clinically
important compounds. Glucuronosyltransferases are the main
phase II biotransformation enzymes, playing a significant role
in the detoxification process of a number of endo- and exog-
enous substances in the organisms of humans and other ver-
tebrates. Catalyzed by the abovementioned group of enzymes,
reactions of glucuronidation of – often dangerous – toxic sub-
stances and drug metabolites lead to an increase of their po-
larity, which facilitates excretion with urine or bile. During
glucuronidation reaction, glucuronic acid in its active form
of UDPGA conjugates with a functional group of the drug,
usually hydroxyl, carboxyl, amino, or thiol, which results in
creation of (usually less toxic) O-, N-, or S-glucuronides.
Multiple variations of the UGT family enzymes are present
in endoplasmic reticulum and cellular membranes. Located
mainly in the liver, they also play a significant role in meta-
bolic transformations occurring outside liver cells—in the al-
imentary canal and kidneys [21].
which, owing to the presence of phase I and II metabolic
enzymes, is commonly used in studying metabolic transfor-
mations of many drugs and xenobiotics [22]. A research on
metabolic transformation of the selected drug first required
determination of suitable reaction conditions by selecting the
amount of cells, substance concentration level, and time of its
incubation with the cells. Popularity of epithelial cell lines in
research on biotransformation is primarily due to the fact that
application of this relatively simple experimental model
quickly yields information that can be generalized. The
Caco-2 cell line was isolated from a colon tumor found in a
72-y-old Caucasian man. During culturing it undergoes spon-
taneous differentiation, and owing to its enterocyte-like struc-
ture, it is used as a model line in in-vitro cultures. Caco-2 cells
produce such enzymes as disaccharidase, peptidase, CYP 450
isoenzymes, glutathione-S transferase, sulfotransferase, and
glucuronidase, as well as transport proteins produced by ab-
sorptive epithelial cells, which participate in transport of sac-
charides, amino acids, peptides, and vitamins. It also produces
p-glycoprotein and multidrug resistance proteins, involved in
transport and metabolism of therapeutic agents. Furthermore,
on the apical side of their surface, the cells of this line produce
small amounts of intestinal mucus [22]. Epithelial cells are
cultured at 37 °C in special incubators with atmospheric con-
tent regulated so that the amount of CO2 equals 5 %, which
imitates the concentration of this gas in blood. Proper humid-
ity protects the culture from desiccating.
Conclusions
The proposed analytical procedure can be useful in pharma-
cokinetics, in experiments on incubating microsomes derived
from liver samples collected from patients treated with antibi-
otics. Besides, although the total level of liver microsomes
P450 does not vary significantly, genetic polymorphism and
susceptibility to induction of particular isoenzymes result in
individual differences in drug metabolism. Ultimately, for
each medicine the characteristic phase I and phase II metabol-
ic biotransformation reactions were identified so as to facili-
tate identification of new substances for personalized antibi-
otic therapy in further advanced research. All the postulated
phase I metabolic reactions are typical for processes catalyzed
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Unchanged in relation to the substrates, the character of the
When a given drug was incubated without cofactor pres-
The proposed study used a cell line of human colon cancer
by isoenzymes of the cytochrome P450 group. It may be con-
cluded that the human liver microsomes with their enzymatic
activity may be very useful in the study of the metabolism of
antibiotic drugs.
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